Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

被引：0
|
作者：
Blisse Vakkalagadda
Charles Frost
Wonkyung Byon
Rebecca A. Boyd
Jessie Wang
Donglu Zhang
Zhigang Yu
Clapton Dias
Andrew Shenker
Frank LaCreta
机构：
[1] Bristol-Myers Squibb Company,Research and Development, Discovery Medicine and Clinical Pharmacology
[2] Pfizer Inc,Global Innovative Pharma Business Clinical Pharmacology
[3] Bristol-Myers Squibb Company,Global Biometric Sciences
[4] Bristol-Myers Squibb Company,Pharmaceutical Candidate Optimization
来源：
American Journal of Cardiovascular Drugs | 2016年 / 16卷
关键词：
Rifampin; Apixaban; Breast Cancer Resistance Protein; Absolute Oral Bioavailability; Single Ascend Dose Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：119 / 127
页数：8
相关论文
共 50 条
  • [31] Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin
    Kadokura, Takeshi
    Groenendaal, Dorien
    Heeringa, Marten
    Mol, Roelof
    Verheggen, Frank
    Garcia-Hernandez, Alberto
    Onkels, Hartmut
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2014, 39 (01) : 1 - 9
  • [32] Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
    Kubitza, Dagmar
    Roth, Angelika
    Becka, Michael
    Alatrach, Abir
    Halabi, Atef
    Hinrichsen, Holger
    Mueck, Wolfgang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (01) : 89 - 98
  • [33] Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin
    Takeshi Kadokura
    Dorien Groenendaal
    Marten Heeringa
    Roelof Mol
    Frank Verheggen
    Alberto Garcia-Hernandez
    Hartmut Onkels
    European Journal of Drug Metabolism and Pharmacokinetics, 2014, 39 : 1 - 9
  • [34] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor
    Becker, Richard C.
    Yang, Hongqiu
    Barrett, Yuchen
    Mohan, Puneet
    Wang, Jessie
    Wallentin, Lars
    Alexander, John H.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) : 183 - 187
  • [35] Rivaroxaban, an oral direct factor Xa inhibitor
    Piccini, Jonathan P.
    Patel, Manesh R.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    Califf, Robert M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (06) : 925 - 937
  • [36] Rivaroxaban: An oral direct inhibitor of factor Xa
    Gulseth, Michael P.
    Michaud, Jessica
    Nutescu, Edith A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (16) : 1520 - 1529
  • [37] New oral Prophylaxis of venous Thromboembolism, Xa Inhibitor Apixaban factor
    Weiche, Iris
    Bauersachs, Rupert
    HAMOSTASEOLOGIE, 2011, 31 (04): : 310 - 310
  • [38] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Wong, Pancras C.
    Pinto, Donald J. P.
    Zhang, Donglu
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (04) : 478 - 492
  • [39] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Pancras C. Wong
    Donald J. P. Pinto
    Donglu Zhang
    Journal of Thrombosis and Thrombolysis, 2011, 31 : 478 - 492
  • [40] The new factor Xa inhibitor: Apixaban
    Bhanwra, Sangeeta
    Ahluwalia, Kaza
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (01) : 12 - 14
12345